



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



⑪ Publication number:

0 510 678 A2

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number: 92107043.9

⑮ Int. Cl.s. C12N 15/80, C12N 15/14,  
C12N 1/16, C12N 1/32,  
//(C12N1/16,C12R1:84)

⑭ Date of filing: 24.04.92

The applicant has filed a statement in accordance with Rule 28 (4) EPC (issue of a sample only to an expert). Accession number(s) of the deposit(s): NRRL B-18114, Y-15851, Y-18014, Y-18017, Y-11430 and Y-11431.

⑯ Priority: 26.04.91 US 691079

⑰ Date of publication of application:  
28.10.92 Bulletin 92/44

⑲ Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IT LI LU NL PT  
SE

⑳ Applicant: PHILLIPS PETROLEUM COMPANY  
5th and Keeler

Bartlesville Oklahoma 74004(US)

㉑ Inventor: Prevatt, William Dudley  
4524 Barlow Drive  
Bartlesville, OK 74006(US)  
Inventor: Sreekrishna, Kotikanyad  
1060 Rolling Meadow Court  
Bartlesville, OK 74006(US)

㉒ Representative: Dost, Wolfgang,  
Dr.rer.nat.,Dipl.-Chem. et al  
Patent- & Rechtsanwälte Bardehle .  
Pagenberg . Dost . Altenburg . Frohwitter .  
Geissler & Partner Galleiplatz 1 Postfach 86  
06 20  
W-8000 München 86(DE)

㉓ Expression of human serum albumin in *pichia pastoris*.

㉔ A process for the production of HSA in *Pichia pastoris* cells comprising cultivating *Pichia pastoris* cells capable of expressing HSA at a pH of about 5.7 to about 6.4 contemporaneously with the expression of HSA.




FIG. 1

BEST AVAILABLE COPY

Field of the Invention

This invention relates to the field of recombinant DNA biotechnology. In one aspect, this invention relates to a process for the improved expression of secreted human serum albumin (HSA) in *Pichia pastoris*.

Background

Human serum albumin is the most abundant plasma protein of adults. The concentration of albumin is 10 40 mg/ml, or 160g of albumin circulating throughout the human body for a 70 Kg adult male. This protein maintains osmotic pressure and functions in the binding and transport of copper, nickel, calcium (weakly, at 2-3 binding sites), bilirubin and protoporphyrin, long-chain fatty acids, prostaglandins, steroid hormones (weak binding with these hormones promotes their transfer across the membranes), thyroxine, triiodothyronine, cysteine, and glutathione. According to Peters, T. and Reed, R. G. in *Albumin: Structure, Biosynthesis and Function*, (Peter, T. and Sjoholm, J. eds.) 1977 p.11-20, over 10,000 kilograms of purified albumin are administered annually in the United States alone to patients with circulatory failure or with albumin depletion.

Currently the only commercial source of HSA is from fractionated blood. Considering the possible dangers of blood borne contaminants and pathogens, it would be a considerable contribution to the 20 commercial production of HSA to develop alternate methods of producing HSA. With the advent of recombinant DNA technology, it is now possible to produce HSA by alternate methods.

HSA has also been expressed in *Saccharomyces cerevisiae* as disclosed by Etcheverry et al. in *Bio/technology*, August 1986, p. 726 and Arjum Singh in EPA 123,544. Etcheverry disclosed HSA expression intracellularly in a concentration of approximately 6 mg/l and the secretion of HSA which 25 remained cell associated. Arjum Singh also disclosed the expression of HSA in *Saccharomyces cerevisiae* in combination with the  $\alpha$ -factor promoter and signal sequence. Singh appears to have been able to achieve an intracellular production level of approximately 25 mg/l and a secreted production level of 3 mg/l. *Pichia pastoris* has also been used to express HSA as is disclosed in EPA 344,459. The concentration of HSA produced in *Pichia pastoris* appears to be about 89 ng HSA/mg of protein. Although the process for 30 producing HSA in recombinant expression systems has been established by these experiments it would be desirable to optimize these processes to achieve the maximum possible HSA production.

Therefore, it would be a significant contribution to the art to provide a process for increasing the yield of HSA from the recombinant expression of HSA in microorganism such as *Pichia pastoris*.

Therefore, it is an object of this invention to provide a process for increasing the yield of HSA produced 35 in a recombinant expression systems.

Summary of the Invention

In accordance, we have discovered a process for improving the secreted expression of HSA in *Pichia pastoris* cells comprising: 40 (a) cultivating in a fermentation broth transformed *Pichia pastoris* cells capable of expressing HSA under conditions suitable for the sustained viability of said *Pichia pastoris* cells under suitable conditions for the expression of HSA by said *Pichia pastoris* cells; and maintaining the pH of said fermentation broth from a pH of from about 5.7 to about 6.0 contemporaneously with the expression of HSA.

Detailed Description of the Figures

Figure 1 provides a representation of plasmid pAO804 which contains a linear site-specific integrative vector in the fragment clockwise from BglII to BglII. The structural gene may be inserted in the unique EcoRI site of this plasmid. This plasmid may be recovered from the plasmid DNA of NRRL B-18114 by EcoRI digest and gel electrophoresis to recover a linear ~7.4 kb EcoRI fragment corresponding to Figure 1.

Figure 2 provides a representation of pHSA13 in circular form.

Figure 3 provides a restriction map of the AOX1 5' regulatory region isolated from *Pichia pastoris*.

Figure 4 provides a restriction map of the DAS1 5' regulatory region isolated from *Pichia pastoris*.

Figure 5 provides a restriction map of the AOX1 3' termination sequence isolated from *Pichia pastoris*.

Figure 6 provides a restriction map of the DAS1 3' termination sequence isolated from *Pichia pastoris*.

Figure 7 provides a representation of pHSA113 in linear form.

Figure 8 provides a representation of plasmid pAO807N which contains a linear site-specific integrative

vector in the fragment clockwise from NotI to NotI. The structural gene may be inserted in the unique EcoRI site of this plasmid.

#### Detailed Description

5

Generally *Pichia pastoris* is optimally grown at from about pH 4.8 to about pH 5.2. Between this pH range *Pichia pastoris* provided with a suitable nutrient media exhibits robust growth. This pH range also appears to result in high levels of expression of several foreign proteins such as hepatitis B surface antigen. This pH range also appeared to provide high levels of expression with human serum albumin (HSA). For 10 example growing *Pichia pastoris* cells which had been transformed with a vector containing a HSA structural gene operably linked to a 5' regulatory region (i.e. a promoter) and a 3' termination sequence, the expression levels of HSA which had been obtained were approximately .71 to .81 grams/liters of HSA in the fermentation broth. However, we have been able to further increase this yield by at least 50% by taking the unprecedented step of shifting the pH of the fermentation broth from about 5.2 to in the range of from about 15 pH 5.7 to about pH 6.4, with a preferred pH range of from about pH 5.7 to about pH 6.0 and most preferably a pH in the range of from pH 5.75 to pH 5.85. The increased secretion levels obtained in the upper limits of the pH range (i.e. from in the range of pH 6.0 to pH 6.4) have been confirmed in shake tube optimization studies which indicate that the presence of yeast extract and peptone together with aeration will provide optimal HSA secretion in shake tubes. However, the use of yeast extract, peptone and excess 20 aeration is not believed necessary in large scale fermentation where the pH can be continuously monitored. We believe that this higher pH level will increase the yield of any *Pichia pastoris* strain transformed with an expression cassette containing a promoter and a structural gene encoding a signal sequence and the mature HSA protein. Further it would appear that this result will be applicable to a variety of heterologous structural genes which encode a signal sequence and a mature heterologous protein. Suitable heterologous 25 proteins which may be expressed at higher levels utilizing this method include but are not limited to heterologous proteins selected from the group consisting of tissue plasminogen activator, albumins (such as human serum albumin), lysozymes (such as bovine lysozyme), interferons (such as gamma-interferon and beta-interferon) and invertase. Each of the heterologous structural genes utilized in the present invention must have a signal sequence operably linked to the 5' end of sequence coding for the mature heterologous 30 protein to effect the secretion of the mature protein. For example the tissue plasminogen activator, human serum albumins, bovine lysozyme, beta-interferon, gamma-interferon and invertase proteins may all be secreted utilizing the native signal sequence. Furthermore these proteins may also be secreted utilizing secretion signal sequences from *Pichia pastoris* such as the acid phosphatase signal sequence disclosed in U.S. Patent Application Serial Number 07/627,539 filed December 14, 1990 by Richard Buckholz 35 assigned to Phillips Petroleum Company (incorporated herein by reference) or the alpha-mating factor signal sequence from *Saccharomyces cerevisiae*.

Utilizing the present invention, HSA secretion levels of approximately 1-3 grams of authentic HSA per liter of fermentation broth have been obtained. This invention thus provides a means for the high level 40 secretion of HSA. Achieving these levels of HSA production is a significant advancement over the prior production levels, since at the level of 1-3 grams per liter the recovery of HSA in high yields with high purities is possible.

To express the HSA structural gene, the gene must be operably linked to a 5' regulatory region and a 3' termination sequence, which forms an expression cassette which will be inserted into a host (usually a 45 microorganism) via a vector (such as a plasmid or linear site-specific integrative vector). Operably linked as used in this context refers to a juxtaposition wherein the 5' regulatory region, structural gene, and 3' termination sequence are linked and configured so as to perform their normal function. 5' regulatory region or promoter as used herein means DNA sequences which respond to various stimuli and provide enhanced 50 rates of mRNA transcription. 3' termination sequence are sequences 3' to the stop codon of a structural gene which function to stabilize the mRNA transcription product of the gene to which the sequence is operably linked (such as sequences which elicit polyadenylation). For the practice of this invention, it is preferred that the ATG of the structural gene be linked with as few intervening deoxyribonucleotides as possible to the 3' end of the 5' regulatory region, preferably about 11 or less deoxyribonucleotides and most preferably 8 or less deoxyribonucleotides. It is also preferred that the adenine and thymine content of the intervening deoxyribonucleotides be in the range of from about 55 percent to about 64 percent. Further, 55 it appears that there are nucleotide preferences for certain specific locations. Counting left from the ATG codon of the structural gene with the first position left being the -1 position, it appears that adenine or cytosine is the most preferred deoxyribonucleotide, in the -2 position the most preferred deoxyribonucleotide is either adenine or thymine, in the -3 position the most preferred deoxyribonucleotide is

adenine or thymine and the most preferred nucleotide at the -4 position is adenine, thymine or cytosine. Currently, it is preferred that the AOX1 or DAS1 5' regulatory region having the restriction maps of Figures 3 and 4 or, the sequences provided as SEQ ID No: 1 and SEQ ID No: 2, respectively, be linked at their 3' end of the sequence to the ATG start codon of the HSA structural gene. One example of an appropriate 5 linkages for the AOX1 5' regulatory region is illustrated below:

Table I

Construct Designation	End of the 5' Regulatory Region for <u>AOX1</u>	Deoxyribonucleotide intervening before ATG start codon
phSA413	5' - TTGAAACG	5' - NONE

Several 5' regulatory regions have been characterized and can be employed in conjunction with the expression of HSA in *Pichia pastoris*. Exemplary 5' regulatory regions are the primary alcohol oxidase (AOX1), dihydroxyacetone synthase (DAS1), glyceraldehyde-3-phosphate dehydrogenase gene (GAP), acid phosphatase gene (PHO1) and the p40 regulatory regions, derived from *Pichia pastoris* and the like. The AOX1 5' regulatory region, DAS1 5' regulatory region and p40 5' regulatory region are described in U.S. Patent 4,855,231, incorporated herein by reference. The GAP 5' regulatory region is disclosed in EPA 374,913 published June 27, 1990, incorporated herein by reference. The PHO1 5' regulatory region is disclosed in U.S. Patent Application 07/672,539 filed December 14, 1990, assigned to Phillips Petroleum Company. The presently preferred 5' regulatory regions employed in the practice of this invention are those characterized by their ability to respond to methanol-containing media, such regulatory regions selected from the group consisting of AOX1, and DAS1. The most preferred 5' regulatory region for the practice of this invention is the AOX1 5' regulatory region.

3' termination sequences should be utilized in the expression cassette as discussed above. 3' termination sequences may function to terminate, polyadenylate and/or stabilize the messenger RNA coded for by the structural gene when operably linked to a gene, but the particular 3' termination sequence is not believed to be critical to the practice of the present invention. A few examples of illustrative sources for 3' termination sequences for the practice of this invention include but are not limited to the *Hansenula polymorpha* and *Pichia pastoris* 3' termination sequences. Preferred are those derived from *Pichia pastoris* such as those selected from the group consisting of the 3' termination sequences of AOX1 gene, DAS1 gene, p40 gene GAP gene, PHO1 gene and HIS4 gene. Particularly preferred is the 3' termination sequence of the AOX1 gene.

*Pichia pastoris* may be transformed with a variety of HSA structural genes (in the inventive transformants discussed herein the HSA structural gene encodes both a signal sequence and a mature HSA protein). HSA structural genes have been sequenced by Lawn et al. Nuc. Acids Res. 9:6105 (1981), and Dugaiczyk et al., Proc. Natl. Acad. Sci. USA 79:71 (1982). These genes may also be obtained by reisolation of the genes by the technique of Lawn et al., Dugaiczyk et al. or synthesized *in vitro* by a custom gene manufacturer such as British Biotechnology, Ltd. One possible method of obtaining a HSA gene would be to screen a human liver cDNA library with oligonucleotide probes or screen a human liver cDNA expression library with anti-HSA antisera to identify HSA expressing cDNAs. One suitable HSA structural gene is provided in SEQ ID NO: 3. Once a structural gene for HSA is recovered, it may be necessary to further tailor the gene. Following the isolation of an HSA structural gene, the gene is inserted into a suitable *Pichia pastoris* vector such as a plasmid or linear site-specific integrative vector.

Plasmid-type vectors have long been one of the basic elements employed in recombinant DNA technology. Plasmids are circular extra-chromosomal double-stranded DNA found in microorganisms. Plasmids have been found to occur in single or multiple copies per cell. Included in plasmid DNA is the information required for plasmid reproduction, e.g. an autonomous replication sequence such as those disclosed by James M. Clegg in U.S. Patent 4,837,148, issued June 6, 1989, incorporated herein by reference. Additionally one or more means of phenotypically selecting the plasmid in transformed cells may also be included in the information encoded in the plasmid.

Suitable integrative vectors for the practice of the present invention are the linear site-specific integrative vectors described by James M. Clegg, in U.S. Patent 4,882,279, issued November 21, 1989, which is incorporated herein by reference. These vectors comprise a serially arranged sequence of at least 1) a first insertable DNA fragment; 2) a selectable marker gene; and 3) a second insertable DNA fragment. An expression cassette containing a heterologous structural gene is inserted in this vector between the first and second insertable DNA fragments either before or after the marker gene. Alternatively, an expression

cassette can be formed *in situ* if a regulatory region or promoter is contained within one of the insertable fragments to which the structural gene may be operably linked.

The first and second insertable DNA fragments are each at least about 200 nucleotides in length and have nucleotide sequences which are homologous to portions of the genomic DNA of the species to be 5 transformed. The various components of the integrative vector are serially arranged forming a linear fragment of DNA such that the expression cassette and the selectable marker gene are positioned between the 3' end of the first insertable DNA fragment and the 5' end of the second insertable DNA fragment. The first and second insertable DNA fragments are oriented with respect to one another in the serially arranged linear fragment as they are oriented in the parent genome.

10 Nucleotide sequences useful as the first and second insertable DNA fragments are nucleotide sequences which are homologous with separate portions of the native genomic site at which genomic modification is to occur. For example, if genomic modification is to occur at the locus of the alcohol oxidase gene, the first and second insertable DNA fragments employed would be homologous to separate portions 15 of the alcohol oxidase gene locus. Examples of nucleotide sequences which could be used as first and second insertable DNA fragments are deoxyribonucleotide sequences selected from the group consisting of the *Pichia pastoris* alcohol oxidase (AOX1) gene, dihydroxyacetone synthase (DAS1) gene, p40 gene glyceraldehyde-3-phosphate dehydrogenase (GAP), acid phosphatase (PHO1) and HIS4 gene. The AOX1 gene, DAS1 gene, p40 gene and HIS4 genes are disclosed in U.S. Patents 4,855,231 and 4,885,242 both 20 incorporated herein by reference. The designation DAS1 is equivalent to the DAS designation originally used in U.S. Patents 4,855,231 and 4,885,242. The GAP gene is disclosed in EPA 374,913 published June 27, 1990 incorporated herein by reference. The PHO1 gene is disclosed in U.S. Patent Application 07/672,539 filed December 14, 1990, assigned to Phillips Petroleum Company, incorporated herein by reference.

25 The first insertable DNA fragment may contain an operable regulatory region which may comprise the regulatory region utilized in the expression cassette. The use of the first insertable DNA fragment as the regulatory region for an expression cassette is a preferred embodiment of this invention. Figure 1 provides a diagram of a vector utilizing the first insertable DNA fragment as a regulatory region for a cassette. Optionally, as shown in Figure 1, an insertion site or sites and a 3' termination sequence may be placed 30 immediately 3' to the first insertable DNA fragment. This conformation of the linear site-specific integrative vector has the additional advantage of providing a ready site for insertion of a structural gene without necessitating the separate addition of a compatible 3' termination sequence.

If the first insertable DNA fragment does not contain a regulatory region, a suitable regulatory region will 35 need to be inserted linked to the structural gene, in order to provide an operable expression cassette. Similarly, if no 3' termination sequence is provided at the insertion site to complete the expression cassette, a 3' termination sequence can be operably linked to the 3' end of the structural gene.

It is also highly desirable to include at least one selectable marker gene in the DNA used to transform 40 the host strain. This facilitates selection and isolation of those organisms which have incorporated the transforming DNA. The marker gene confers a phenotypic trait to the transformed organism which the host did not have, e.g. restoration of the ability to produce a specific amino acid where the untransformed host 45 strain has a defect in the specific amino acid biosynthetic pathway, or provides resistance to antibiotics and the like. Exemplary selectable marker genes may be selected from the group consisting of the HIS4 gene (disclosed in U.S. Patent 4,885,242) and the ARG4 gene (disclosed in U.S. Patent 4,818,700 incorporated herein by reference) from *Pichia pastoris* and *Saccharomyces cerevisiae*, the invertase gene (SUC2) (disclosed in U.S. Patent 4,857,467 incorporated herein by reference) from *Saccharomyces cerevisiae*, or the G418<sup>R</sup>/kanamycin resistance gene from the *E. coli* transposable elements Tn601 or Tn903.

Those skilled in the art recognize that additional DNA sequences can also be incorporated into the vectors employed in the practice of the present invention, such as, for example, bacterial plasmid DNA, bacteriophage DNA, and the like. Such sequences enable the amplification and maintenance of these vectors in bacterial hosts.

50 The insertion of the HSA structural gene into suitable vectors may be accomplished by any suitable technique which cleaves the chosen vector at an appropriate site or sites and results in at least one operable expression cassette containing the HSA structural gene being present in the vector. Ligation of the HSA structural gene may be accomplished by any appropriate ligation technique such as utilizing T4 DNA ligase.

55 The initial selection, propagation, and optional amplification of the ligation mixture of the HSA structural gene and a vector is preferably performed by transforming the mixture into a bacterial host such as *E. coli* - (although the ligation mixture could be transformed directly into a yeast host but, the transformation rate would be extremely low). Suitable transformation techniques for *E. coli* are well known in the art.

Additionally, selection markers and bacterial origins of replication necessary for the maintenance of a vector in a bacterial host are also well known in the art. The isolation and/or purification of the desired plasmid containing the HSA structural gene in an expression system may be accomplished by any suitable means for the separation of plasmid DNA from the host DNA. Similarly the vectors formed by ligation may be tested, preferably after propagation, to verify the presence of the HSA gene and its operable linkage to a regulatory region and a 3' termination sequence. This may be accomplished by a variety of techniques including but not limited to endonuclease digestion, gel electrophoresis, or Southern hybridization.

Transformation of plasmids or linear vectors into yeast hosts may be accomplished by suitable transformation techniques including but not limited to those taught by Cregg and Barringer, U.S. Patent 4,929,555; Hinnen et al., Proc. Natl. Acad. Sci. 75, (1978) 1929; Ito et al., J. Bacteriol. 153, (1983) 163; Cregg et al. Mol. Cell Biol. 5 (1985), pg. 3376; D. W. Stroman et al., U.S. Patent 4,879,231, issued November 7, 1989; or Sreekrishna et al., Gene, 59 (1987), pg. 115. Preferable for the practice of this invention is the transformation technique of Cregg et al. (1985). It is desirable for the practice of this invention to utilize an excess of linear vectors and select for multiple insertions by Southern hybridization.

The yeast host for transformation may be any suitable methylotrophic yeast. Suitable methylotrophic yeasts include but are not limited to yeast capable of growth on methanol selected from the group consisting of the genera *Hansenula* and *Pichia*. A list of specific species which are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 (1982). Presently preferred are methylotrophic yeasts of the genus *Pichia* such as the auxotrophic *Pichia pastoris* GS115 (NRRL Y-15851); *Pichia pastoris* GS190 (NRRL Y-18014) disclosed in U.S. Patent 4,818,700; and *Pichia pastoris* PPF1 (NRRL Y-18017) disclosed in U.S. Patent 4,812,405. Auxotrophic *Pichia pastoris* strains are also advantageous to the practice of this invention for their ease of selection. It is recognized that wild type *Pichia pastoris* strains (such as NRRL Y-11430 and NRRL Y-11431) may be employed with equal success if a suitable transforming marker gene is selected, such as the use of SUC2 to transform *Pichia pastoris* to a strain capable of growth on sucrose or an antibiotic resistance marker is employed, such as G418.

Transformed *Pichia pastoris* cells can be selected for by using appropriate techniques including but not limited to culturing previously auxotrophic cells after transformation in the absence of the biochemical product required (due to the cell's auxotrophy), selection for and detection of a new phenotype ("methanol slow"), or culturing in the presence of an antibiotic which is toxic to the yeast in the absence of a resistance gene contained in the transformant.

Isolated transformed *Pichia pastoris* cells are cultured by appropriate fermentation techniques such as shake flask fermentation, high density fermentation or the technique disclosed by Cregg et al. in, High-Level Expression and Efficient Assembly of Hepatitis B Surface Antigen in the Methylotrophic Yeast, Pichia Pastoris 5 Bio/Technology 479 (1987). Isolates may be screened by assaying for HSA production to identify those isolates with the highest HSA production level.

The cultivation of transformed *Pichia pastoris* can be conducted in an aqueous continuous or batch-fed manner, utilizing a variety of carbon-energy sources and/or nutrient sources. For the practice of the present invention, batch-fed fermentation is preferred. Suitable carbon-energy sources for growing *Pichia pastoris* include but are not limited to the carbon-energy source selected from the group consisting of methanol, glycerol, sorbitol, glucose, fructose and combinations of any two or more thereof. Preferred carbon-energy sources for growing *Pichia pastoris* are carbon-energy sources selected from the group consisting of methanol, glycerol, and combinations thereof. A suitable nutrient source or media for *Pichia pastoris* would include at least one nitrogen source, at least one phosphate source, at least one source of minerals such as iron, copper, zinc, magnesium, manganese, calcium, and other trace elements, and vitamins (such as biotin, pantothenic acid, and thiamine as required).

Suitable sources of at least one carbon-energy source and nutrients can be obtained from a variety of sources or may consist of a single source. However, preferred are at least one carbon-energy source and/or nutrient sources which have a defined character. One carbon-energy source and/or nutrient composition which has proven effective is:

Table II

Carbon-Energy Source and Nutrients	
Component per Liter of Water	
5	Carbon-energy Source (glycerol) 50.0 g/l
10	H <sub>3</sub> PO <sub>4</sub> (85%) 21 ml/l
	CaSO <sub>4</sub> · 2H <sub>2</sub> O 0.9 g/l
15	K <sub>2</sub> SO <sub>4</sub> 14.28 g/l
	MgSO <sub>4</sub> · 7H <sub>2</sub> O 11.7 g/l
	KOH 3.9 g/l
	Peptone 10.0 g/l
	<sup>1</sup> Yeast Extracts 5.0 g/l
	<sup>2</sup> Minerals and Trace Metals 1.0 ml/l

<sup>1</sup>Yeast extract is Amberex™ 1003 which is available from and a trademark of Universal Foods Corporation, Milwaukee, Wisconsin.

<sup>2</sup>Minerals and trace metals are FeSO<sub>4</sub> · 7H<sub>2</sub>O 65.0 g/l, CuSO<sub>4</sub> · 5H<sub>2</sub>O 6.0 g/l, ZnSO<sub>4</sub> · 7H<sub>2</sub>O 20 g/l, MnSO<sub>4</sub> 3.0 g/l and H<sub>2</sub>SO<sub>4</sub> 5.0 ml/l

20 The yeast extracts utilized in the present invention include but are not limited to yeast extracts selected from the group consisting of Amberex™ 1003 and Bacto™ Yeast Extract (Difco Laboratories Incorporated). Alternatively, corn steep liquor could be used to replace yeast extracts as a source of nitrogen.

25 Trace metals utilized in the present invention are those trace metals generally utilized in the yeast growth provided in an amount sufficient to not limit the growth rate or HSA production of *Pichia pastoris* which include but are not limited to trace metals selected from the group consisting of cobalt, molybdenum, iron, copper, zinc, and manganese.

30 The fermentation temperature should generally range from about 20°C to about 35°C and preferably should be about 30°C.

35 The dissolved oxygen content in the fermentation vessel where the fermentation is conducted in a batch-fed manner may range from about 20 percent to about 80 percent of saturation and preferably will range from about 30 percent to about 60 percent of saturation.

40 After the *Pichia pastoris* strains transformed with a vector containing the HSA structural gene have been cultivated to a high density, the transformed strains should then be induced to express HSA at a pH of from about 5.7 to about 6.0. For example, if this technique is employed with a strain transformed with a linear expression cassette containing a methanol inducible regulatory region, the culture would first be grown to the desired density on minimal salts, biotin and 5 percent glycerol by weight. The pH should be adjusted to 5.8 (with ammonia) with a temperature of about 30°C and a dissolved oxygen concentration of about 20 percent of saturation. After the glycerol is exhausted, the promoter would be induced by beginning a slow methanol feed. The feed should provide methanol to the culture at a rate at least sufficient to maintain the viability of the culture but the maximum methanol concentration in contact with the culture should be no more than about 5.0 percent by weight. The HSA secretion can be monitored during the methanol feeding by sampling the HSA present in the cell free broth. Suitable test for quantifying the amount of HSA produced are known to those skilled in the art, such as running polyacrylamide gels. The methanol feed should be continued until the HSA concentration reaches an acceptable level. Generally, the HSA production will peak after about 120 hours on methanol feed.

45 If the transformed *Pichia pastoris* cells are grown in shake tubes or shake flasks instead of pH controlled fermenter, additional steps should be taken to assure the maximum yields of secreted proteins, such as HSA. Specifically, it is recommended that the media used be modified from that used in fermenter to a complex media and the aeration be increased. The complex media utilized in the shake flasks and shake tubes should contain added amino acids. The amino acids may be in a defined media containing glutamic acid, methionine, lysine, leucine, isoluecine and other amino acids or through a complex media supplement, such as yeast extract or casamino acids. The relative concentrations of the added amino acids should generally range from about 2.5 mg/liter to about 10 mg/liter with the preferred range being from about 4 mg/liter to about 6 mg/liter of glutamic acid, methionine, lysine, leucine and isoluecine and from about 0.5 mg/liter to about 3 mg/liter of the remaining amino acid (however, histidine may be omitted entirely from the added amino acids). If yeast extract is used in place of the added amino acids, it is preferred that the yeast extract be provided in a concentration of in the range of from about 1 g/liter to

about 15 g/liter be utilized in the media and most preferably the yeast extract will be provided in a concentration of 10 g/liter. It has also been found desirable to add peptone to the media to improve secretion in shake tubes and shake flasks. For optimum secretion that peptone be used with the yeast extract in a concentration of from in the range of from about 1 g/liter to about 50 g/liter, and most preferably 5 in a concentration of about 20 g/liter. As a guideline, it is generally recommended that the peptone concentration be twice the yeast extract concentration.

Aeration in shake flask and shake tube growth of transformed *Pichia pastoris* appears to be an important parameter in obtaining optimum secretion. To insure adequate aeration, it is recommended that shake tube or flask have a large aperture covered with an air permeable cap. Suitable air permeable caps 10 can be made of a loose filter material, such as cheese cloth. One suitable shake flask for this invention is the Tunair shake flask. Generally, low baffle shake flasks are also recommended to avoid excessive foaming. Shaker speed for aeration is recommended to be in the range of from about 250 rpm to about 300 rpm.

After a suitable cell density is achieved in the shake flask or shake tube, the cells may be recovered 15 then resuspended in a medium containing methanol in place of the carbon source used for growth to induce the secretion of protein. The flask or shake tubes may then be monitored on a regular basis to determine when the desired level of production has been achieved.

The invention will now be described in greater detail in the following non-limiting examples.

20 Examples

General information pertinent to the Examples:

Strains

25 *Pichia pastoris* GS115 (his 4) NRRL Y-15851  
*E. coli* DG75' (hsd1, leu6, lacY, thr-1, supE44, tonA21, lambda)

30 Buffers, Solutions and Media

35 The buffers, solutions, and media employed in the following examples have the compositions given below:

dH<sub>2</sub>O

deionized H<sub>2</sub>O that has been treated with a milli-Q (Millipore) reagent water system.

35 1M Tris buffer

121.1 g Tris base in 800 mL of H<sub>2</sub>O; adjust pH to the desired value by adding concentrated (35%) aqueous HCl; allow solution to cool to room temperature before final pH adjustment, dilute to a final volume of 1 L.

40 TE buffer

1.0 mM EDTA

in 0.01 M (pH 8.0) Tris buffer

1 M sorbitol

25 mM EDTA

50 mM DTT, added prior to use

--adjust to pH 8

9.1 g sorbitol

1.47 g Sodium citrate

0.168 g EDTA

--pH to 5.8 with HCl in 50 ml

dH<sub>2</sub>O and autoclave

50

CaS

1 M sorbitol

10 mM CaCl<sub>2</sub>

--filter sterilize

SOS:

1 M sorbitol

55

PEG

0.3x YPD

10 mM CaCl<sub>2</sub>

20% polyethylene glycol-3350

10 mM CaCl<sub>2</sub>

		10 mM Tris-HCl (pH 7.4) --filter sterilize
5	Solution A	0.2 M Tris-HCl (pH 7.5) 0.1 M MgCl <sub>2</sub> 0.5 M NaCl 0.01 M dithiothreitol (DTT)
	Solution B	0.2 M Tris-HCl (pH 7.5) 0.1 M MgCl <sub>2</sub> 0.1 M DTT
10	Solution C (keep on ice)	4 $\mu$ l solution B 4 $\mu$ l 10 mM dATP 4 $\mu$ l 10 mM dTTP 4 $\mu$ l 10 mM dGTP 4 $\mu$ l 10 mM dCTP 4 $\mu$ l 10 mM ATP 5 $\mu$ l T <sub>4</sub> ligase (2 U/ $\mu$ l) 12 $\mu$ l H <sub>2</sub> O
15		Recipe for Solution C was modified from Zoller & Smith
20	LB Broth, 1 liter	5.0 g yeast extract 10.0 g tryptone 5.0 g NaCl 96.8 g Trizma Base 9.74 g glycine water to 1 liter
	10X Transfer Buffer	
25	Ligation Buffer	50 mM Tris-HCl (pH 7.4) 10 mM MgCl <sub>2</sub> 10 mM dithiothreitol 1 mM ATP
30	Phosphatase Buffer	50 mM Tris-HCl (pH 9.0) 1 mM MgCl <sub>2</sub> 1 mM ZnCl <sub>2</sub> 1 mM spermidine
	<u>Bsu36I buffer</u>	100 mM NaCl 10 mM Tris-HCl (pH 7.4) 10 mM MgCl <sub>2</sub> 100 $\mu$ g/ml BSA
35		60 mM NaCl 10 mM Tris-HCl, pH 7.5 7 mM MgCl <sub>2</sub> 100 $\mu$ g/ml BSA
	<u>Csp45I buffer</u>	
40		50 mM Tris-HCl, pH 8.0 10 mM MgCl <sub>2</sub> 100 $\mu$ g/ml BSA
	REact 1 buffer	
45	REact 2 buffer REact 3 buffer HS buffer	REact 1 buffer + 50 mM NaCl REact 1 buffer + 100 mM NaCl 50 mM Tris-HCl, pH 7.5 10 mM MgCl <sub>2</sub> 100 mM NaCl
		1 mM DTT 100 $\mu$ g/ml BSA
50	10X Basal Salts	42 mls Phosphoric Acid, 85% 1.8 g Calcium Sulfate • 2H <sub>2</sub> O 28.6 g Potassium Sulfate 23.4 g Magnesium Sulfate • 7H <sub>2</sub> O 6.5 g Potassium Hydroxide 6.0 g Cupric Sulfate • 5H <sub>2</sub> O 0.08 g Sodium Iodide
55	Ptm, Trace Salts Solution	

5		3.0 g Manganese Sulfate • H <sub>2</sub> O 0.2 g Sodium Molybdate • H <sub>2</sub> O 0.02 g Boric Acid 0.5 g Cobalt Chloride 20.0 g Zinc Chloride 65.0 g Ferrous Sulfate • H <sub>2</sub> O 0.20 g Biotin 5.0 mls Sulfuric Acid 10 g bacto yeast extract 20 g peptone 10 g dextrose water to 1 liter
10	YPD (yeast extract peptone dextrose medium)	13.4 g yeast nitrogen base with ammonium sulfate, and without amino acids 400 µg biotin 10 ml glycerol water to 1 liter
15	MGY (minimal glycerol medium)	13.4 g yeast nitrogen base with ammonium sulfate and without amino acids 400 µg biotin 10 ml glycerol water to 1 liter
20	MM (minimal methanol medium)	Same as MGY, except that 5 ml methanol is used in the place of 10 ml glycerol.
25	SDR (supplemented dextrose regeneration medium):	13.4 g yeast nitrogen base with ammonium sulfate and without amino acids 400 µg biotin 182 g sorbitol 10 g glucose 2 g Histidine assay mix (Gibco) 50 mg glutamine 50 mg methionine 50 mg lysine 50 mg leucine 50 mg isoleucine 10 g agarose water to 1 liter
30	BMGR (Buffered minimal glycerol-enriched medium)	100 ml/liter Potassium phosphate buffer, (pH 6.0) 13.4 grams/liter Yeast nitrogen base with ammonium sulfate 400 µg/liter biotin 10 ml/liter glycerol Amino acids glutamic acid, methionine, lysine, leucine and isoleucine: each at 5 mg/liter; all the other amino acids except histidine at 1 mg/liter Nucleotides adenine sulfate, guanine hydrochloride, uracil, and xanthine, each at 40 µg/liter Vitamins thiamine hydrochloride, riboflavin, and calcium pantothenate, each at 2 µg/liter; pyridoxide hydrochloride and nicotinic acid, each at 4 µg/liter; pyridoxamine hydrochloride and pyridoxal hydrochloride, each at 1 µg/liter; para-amino benzoic acid at 0.3 µg/liter; folic acid at 0.03 µg/liter Trace minerals magnesium sulfate at 800 µg/liter; ferrous sulfate at 40 µg/liter;
35		
40		
45		
50		
55		

5	BMGY (Buffered minimal glycerol-complex medium)	manganese sulfate at 80 $\mu$ g/liter; sodium chloride at 40 $\mu$ g/liter 100 ml/liter potassium phosphate buffer, (pH 6.0) 13.4 grams/liter yeast nitrogen base with ammonium sulfate and without amino acids biotin at 400 $\mu$ g/liter glycerol at 10 ml/liter yeast extract at 10 g/liter peptone at 20 g/liter
10	BMMR (Buffered minimal methanol-enriched medium)	Same as BMGR, with the exception that 5 ml methanol/liter is added in the place of glycerol
	BMMY (Buffered minimal methanol -complex medium)	Same as BMGY, with the exception that 5 ml methanol/liter is added in the place of glycerol

15 Techniques

Suitable techniques for recombinant DNA lab work may be found in many different references including but not limited to: Methods in Enzymology, (Orlando, FL: Academic Press, Inc.), particularly Volume 152, 20 published as, Guide to Molecular Cloning Techniques, by Berger and Kimmel (Orlando, FL: Academic Press, Inc., 1987) and Molecular Cloning/A Laboratory Manual, by Sambrook et al., 2d ed. (Cold Spring Harbor Laboratory Press, 1989) and which are all hereby incorporated by reference.

25 Example I  
Construction of 5'-exact HSA expression vector pHSA313

The pHSA313 vector was constructed to provide a vector with an exact linkage between the 3' end of the native AOX1 5' regulatory region (promoter) and the start codon of the HSA structural gene.

30 A. Creation of pHSA113 $\Delta$ Cla  
About 200 ng of pHSA113, disclosed in European Patent Application 0 344 459 which is herein incorporated by reference, (see Figure 7) was digested at 37 °C for 1 hour with 1 unit of Cla in 20  $\mu$ l of REact 1 buffer. The digestion mixture was brought to 100  $\mu$ l with water and extracted once with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 V/V), followed by extracting the aqueous layer with an equal volume of chloroform:isoamyl alcohol (24:1). The DNA in the aqueous phase was precipitated by adjusting the NaCl concentration to 0.2 M and adding 3 volumes of cold ethanol. The mixture was allowed to stand on ice (4 °C) for 10 minutes and the DNA precipitate was collected by centrifugation for 30 minutes at 10,000 x g in a microfuge at 4 °C. The DNA pellet was washed 2 times with 70% aqueous cold ethanol. The washed pellet was vacuum dried and dissolved in 10  $\mu$ l water to which 2  $\mu$ l of 10 x ligation buffer, 2  $\mu$ l of 1 mg/ml BSA, 6  $\mu$ l of water and 1 unit T<sub>4</sub> DNA ligase were added. The mixture was incubated overnight at 4 °C and a 10  $\mu$ l aliquot was used to transform E. coli DG75' (Maniatis, et al.) to obtain pHSA113 $\Delta$ Cla, which represents the deletion of HIS4 and 3'AOX1, along with small stretches of pBR322 sequences used 40 to link these sequences. The deletion of the HIS4, 3' AOX1 and pBR322 sequences removes one of two Csp45I sites present in the pHSA113 vector. The remaining Csp45I site is in the AOX1 5' regulatory region (promoter).

45 B. Creation of pXHSA113 $\Delta$ Cla  
50 Digest 5  $\mu$ g of pHSA113 $\Delta$ Cla for 1 hour at 37 °C with 10 units of BstEll in 100  $\mu$ l of REact 2 buffer. The digestion mixture was extracted with phenol and precipitated as detailed in step A. The DNA precipitate was dissolved in 100  $\mu$ l of Csp45I buffer and digested at 37 °C for 2 hours in the presence of 10 units of Csp45I. The digested DNA was then phenol extracted and precipitated as described in step A. The DNA precipitate was dissolved in 20  $\mu$ l of water and 10  $\mu$ l aliquots were loaded on 2 neighboring wells of a 0.9% agarose gel. Following electrophoresis, the gel portion corresponding to one of the lanes was stained and this was used to locate the position of the Csp45I-BstEll fragment of pHSA113 $\Delta$ Cla in the unstained lane. The gel portion containing the larger Csp45I-BstEll fragment was excised out and the DNA in the gel was

5 electroeluted into 500  $\mu$ l of 5 mM EDTA, pH 8.0. The DNA solution was phenol extracted as detailed in step A and the DNA precipitate was dissolved in 100  $\mu$ l water. The larger Csp45I-BstEII fragment was then ligated with the BstEII-Csp45I oligonucleotide linker described below. An aliquot (10  $\mu$ l) was ligated overnight at 4°C with 20 ng of annealed linker oligonucleotides 5'-CGAAACG ATG AAG TGG (SEQ ID NO:4) and 5'-GTTACCCACTTCATCGTTT (SEQ ID NO:5) in 20  $\mu$ l ligase buffer containing 100  $\mu$ g/ml BSA and 1 unit of T4 DNA ligase. The ligation mixture was used to transform E. coli DG75' to obtain pXHSA113 $\Delta$ Cla. The pXHSA113 $\Delta$ Cla vector by virtue of the linker described above has an exact linkage between the 3' end of the native AOX1 5' regulatory region (promoter) and the HSA ATG start codon with no extraneous DNA sequences.

10

### C. Creation of pHSA313

15 1  $\mu$ g of pXHSA113 $\Delta$ Cla was digested for 4 hours at 37°C with ClaI in 100  $\mu$ l of REact 1 buffer. Following digestion the reaction mixture was adjusted to alkaline phosphatase buffer conditions and treated with 10 units of calf intestinal alkaline phosphatase in a 200  $\mu$ l reaction volume for 30 minutes at 37°C. Phosphatase treatment was terminated by phenol extraction and the DNA was precipitated and dissolved in water at a concentration of approximately 10 ng/ $\mu$ l as described in step A and stored at -20°C.

20 1  $\mu$ g of pAO807N (Figure 8, construction of which is described in European Patent Application 0 344 459) was digested for 4 hours at 37°C with PstI in 100  $\mu$ l of REact 2 buffer. The digested DNA was adjusted to alkaline phosphatase buffer conditions and treated with 10 units of calf intestinal alkaline phosphatase in a 200  $\mu$ l reaction volume for 15 minutes at 55°C. At the end of 15 minutes another 10 units of phosphatase was added and incubated for 15 minutes. Phosphatase treatment was terminated by phenol extraction and the DNA was precipitated as described in step A. DNA was digested for 4 hours at 37°C with 5 units of ClaI in 100  $\mu$ l REact 1 buffer containing 100  $\mu$ g/ml BSA, followed by phenol extraction and precipitation of DNA as outlined in step A. The DNA precipitate was dissolved in water at a concentration of approximately 20 ng/ $\mu$ l.

25 Approximately 100 ng (10  $\mu$ l) of ClaI cleaved-phosphatased pXHSA113 $\Delta$ Cla was mixed with approximately 80 ng of PstI digested-phosphatased and ClaI-cleaved pAO807N (4  $\mu$ l), 4  $\mu$ l of 5X ligase buffer, 2  $\mu$ l of 1 mg/ml BSA and ligated overnight at 4°C using 1 unit of T4 DNA ligase. The ligation mixture was used to transform E. coli DG75' to obtain pHSA313. The pHSA313 plasmid from this ligation contains the complete pXHSA113 $\Delta$ Cla sequence linked to the HIS4 gene and the AOX1 3' second insertable sequence derived from AO807N. The relative orientation of the components of the pHSA313 plasmid is the same as that shown in Figure 7 for plasmid pHSA113.

35

### Example II

#### Construction of Expression Vector pPGP1

40 The expression vector pPGP1 was constructed in the following manner. pXHSA113 $\Delta$ Cla (see Example I) was digested with Bsu36I and PvuII (partial) and the vector backbone was isolated. An HSA structural gene on a PvuII-Bsu36I fragment analogous to the structural gene contained in pHSA113 (disclosed in European Patent Application 0 344 459) was ligated to this vector backbone to obtain pPGP1 $\Delta$ Cla. About 100 ng of pPGP1 $\Delta$ Cla was digested with ClaI at 37°C for 1 hour. The DNA was recovered as in Example I. About 100 ng of pAO807N (shown herein in Figure 8 and disclosed in European Patent Application 0 344 459) was digested with PstI, alkaline phosphatase treated and then digested with ClaI as detailed in Example I C. This fragment was then ligated to ClaI cleaned, alkaline phosphatase treated pPGP1 $\Delta$ Cla to obtain pPGP1. (GS115 pPGP1-9-6 is a clone which was obtained by transformation of Pichia pastoris GS115 with pPGP1 and this clone was used in fermentation).

50

### Example III

#### Construction of 5' & 3' exact HSA expression plasmid pHSA413

55 The pHSA413 vector was constructed to provide a vector with an exact linkage between the 3' end of the AOX1 5' regulatory region and the start codon fo the HSA structural gene as well as an exact linkage between the 5' end of the AOX1 3' termination sequence and the 3' end of the HSA structural gene.

#### A.. Creation of pXXHSA113 $\Delta$ Cla

1  $\mu$ g of pXHSA113 $\Delta$ Cla was digested for 4 hours at 37°C with 10 units of EcoRI in 100  $\mu$ l REact 3 buffer. The digestion mixture was phenol extracted and DNA precipitated as detailed in Example VI. DNA precipitate was dissolved in 20  $\mu$ l water and digested for 1 hour at 37°C with 20 units of Bsu36I in 100  $\mu$ l of Bsu36I buffer. The digestion mixture was phenol extracted, DNA precipitated and dissolved in 100  $\mu$ l of water as detailed in Example VI. Approximately 100 ng of EcoRI and Bsu36I-cleaved DNA was mixed with 10 ng of annealed oligonucleotides 5'-TTAGGCTTATAAG (SEQ ID NO:6) and 5'-AATTCTTATAAGCC (SEQ ID NO:7) and ligated overnight at 4°C in 20  $\mu$ l of T<sub>4</sub> DNA ligase buffer containing 100  $\mu$ g/ml BSA and 10 units of T<sub>4</sub> DNA ligase. The ligation mixture was used to transform E. coli to obtain pXXHSA113 $\Delta$ Cla. In this plasmid the sequence between Bsu36I and EcoRI (SEQ ID NO:8) present in pXHSA113 $\Delta$ Cla shown below

10

Bsu36I

15

5 'CCTT~~AGG~~CTTATAACATCTCTACATTTAAAGC~~AT~~CTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCA  
AAAGCTTATT~~C~~ATCTGTGTTTCTTTGTTGGTGTAAGCCAACACCC~~T~~GCTAAAAAACATAAAATTCTTTAATC  
ATTTG~~C~~CTCTTTCTGTGCTTC~~A~~TTAATAAAAAATGGAAAGAATCTAAAAAAAAAAAAAGGAATTC

EcoRI

20

is replaced by 5 'CC TTA GGC TTA TAA GAATTC (SEQ ID NO:9)

Bsu36IEcoRI

25

B. Creation of pHSA413

1  $\mu$ g of pXXHSA113 $\Delta$ Cla was digested for 4 hours at 37°C with Clal in 100  $\mu$ l of REact 1 buffer. Following digestion the reaction mixture was adjusted to alkaline phosphatase buffer conditions and treated with 10 units of calf intestinal alkaline phosphatase in 200  $\mu$ l reaction volume for 30 minutes at 37°C. 30 Phosphatase treatment was terminated by phenol extraction and the DNA was precipitated and dissolved in water at a concentration of approximately 10 ng/ $\mu$ l as described in step A and stored at -20°C.

Approximately 100 ng (10  $\mu$ l) of Clal cleaved-phosphatased pXXHSA113 $\Delta$ Cla was mixed with approximately 80 ng (4  $\mu$ l) of PstI digested phosphatased and Clal-cleaved pAO807N (see paragraph 2 in step 3 of Example VI), 4  $\mu$ l of 5X ligase buffer, 2  $\mu$ l of 1 mg/ml BSA and ligated overnight at 4°C using 1 unit of T<sub>4</sub> 35 DNA ligase. The ligation mixture was used to transform E. coli DG75' to obtain pHSA413. The pHSA413 plasmid from theis ligation contains the complete pXHSA113 $\Delta$ Cla sequence linked to the HIS4 gene and the AOX1 3' second insertable sequence derived from AO807N. The relative orientation of the components of the pHSA413 plasmid is the same as that shown in Figure 7 for plasmid pHSA113.

40

Example IVTransformation of *Pichia pastoris* with pHSA313, pHSA413, and pPGP1

45

A.. Vector preparation

About 10  $\mu$ g each of pHSA313, pHSA413, pPGP1, and pAO807N (negative control) were digested for 12 hours at 37°C in 200  $\mu$ l of HS buffer with 50 units of NotI. The digested DNA samples were phenol extracted, precipitated as described in Example VI, dissolved in 20  $\mu$ l of CaS, and were then used for transformation of *Pichia pastoris* GS115. About 10  $\mu$ g each of pHSA313, pHSA413, and pAO807N were 50 also digested with 20 units of SstI for 12 hours at 37°C in 200  $\mu$ l of REact 2 buffer containing 100  $\mu$ g/ml of BSA. The digested DNA samples were extracted with phenol, precipitated as described in Example VI and dissolved in 20  $\mu$ l of CaS.

55

B. Cell Growth

*Pichia pastoris* GS115 (NRRL Y-15851) was inoculated into about 10 ml of YPD medium and shake cultured at 30°C for 12-20 hours. 100 ml of YPD medium was inoculated with a seed culture to give an OD<sub>600</sub> of about 0.001. The medium was cultured in a shake flask at 30°C for about 12-20 hours. The

culture was harvested when the  $OD_{600}$  was about 0.2-0.3 by centrifugation at 1555 g for 5 minutes using a Sorvall RB5C.

C. Preparation of Spheroplasts

5 The cells were washed in 10 ml of sterile water, and then centrifuged at 1500 g for 5 minutes. (Centrifugation is performed after each cell wash at 1500 g for 5 minutes using a Sorvall RT6000B unless otherwise indicated.) The cells were washed once in 10 ml of freshly prepared SED, once in 10 ml of sterile 1M sorbitol, and finally resuspended in 10 ml of SCE buffer. 7.5  $\mu$ l of 3 mg/ml Zymolyase (100,000 units/g, 10 obtained from Miles Laboratories) was added to the cell suspension. The cells were incubated at 30°C for about 10 minutes. (A reduction of 60% in  $OD_{600}$  in 5% SDS can be utilized as a correct time marker.) The spheroplasts were washed in 10 ml of sterile 1 M sorbitol by centrifugation at 700 g for 5-10 minutes. 10 ml of sterile CaS was used as a final cell wash, and the cells were centrifuged again at 700 g for 5-10 minutes and then resuspended in 0.6 ml of CaS.

15 D. Transformation

20 *Pichia pastoris* GS115 cells were transformed with 10  $\mu$ g of linearized DNA (see step A) using the spheroplast transformation technique of Sreekrishna et al, Gene 59, 115-125 (1987). DNA samples were added (up to 20  $\mu$ l volume) to 12 x 75 mm sterile polypropylene tubes. (DNA should be in a suitable buffer such as TE buffer or CaS.) 100  $\mu$ l of spheroplasts were added to each DNA sample and incubated at room 25 temperature for about 20 minutes. 1 ml of PEG solution was added to each sample and incubated at room temperature for about 15 minutes and centrifuged at 700 g for 5-10 minutes. SOS (150  $\mu$ l) was added to the pellet and incubated for 30 minutes at room temperature. Finally 850  $\mu$ l of 1M sorbitol was added.

25 E. Regeneration of Spheroplasts

30 A bottom agarose layer of 20 ml of regeneration agar SDR was poured per plate at least 30 minutes before transformation samples were ready. In addition, 8 ml aliquots of regeneration agar were distributed to 15 ml conical bottom Corning tubes in a 45°C water bath during the period that transformation samples 35 were in SOS. Aliquots of 50 or 250  $\mu$ l of the transformed sample was added to the 8 ml aliquots of molten regeneration agar held at 45°C and poured onto plates containing the solid 20 ml bottom agar layer. The plates were incubated at 30°C for 3-5 days.

35 F. Selection of Transformants

40 Transformants were selected for by culturing on SDR, a media lacking histidine. The colonies which grew in the absence of histidine were also screened for "methanol-slow" phenotype, indicating displacement of the AOX1 structural gene by the NotI DNA fragment (in the case of transformants obtained using NotI linearized vectors. Several transformed GS115 cells showing "methanol-normal" (those obtained with SstI linearized DNA) and methanol-slow were then cultured and assayed for the production of HSA.

Example V

45 Methanol Induced Secretion of HSA in *Pichia pastoris* Integrative Transformants

50 *Pichia pastoris* GS115 strains transformed with pHSA313, pHSA413, and pPGP1 were analysed for HSA secretion in shake tube cultures. Both methanol-slow and methanol-normal strains were used. In each case 36 independent clones were studied. Transformants obtained with pAO807N served as negative controls. A protocol was developed to ensure efficient secretion and stable accumulation of HSA in the culture medium.

55 Cells were grown to saturation in 10 ml BMGR or BMGY, and were placed in 50 ml tubes (2-3 days). The cells would be in the range of 10-20  $A_{600}$  units. The cells were harvested, the supernatant liquid was discarded, and then the pellet was resuspended in 2 ml of BMMR or BMMY. The tube was covered with a sterile gauze (cheese cloth) instead of a cap. The tube(s) were then returned to a 30°C shaker. At the end of 2-3 days, the cells were pelleted, and the supernatant assayed for product. The pellets could be resuspended with fresh medium and returned to the shaker for renewed secretion. With *Pichia*-HSA strains, 10  $\mu$ l of media supernatant was sufficient for analysis by SDS-PAGE followed by Coomassie staining. Under

these conditions a single band of 67 kD corresponding to HSA was observed. There was no significant difference between the expression levels of GS115/pHSA313 vs GS115/pHSA413 transformants, suggesting that deleting the 3' untranslated sequences from the HSA gene present in pHSA313 did not significantly affect expression levels. No significant difference in the HSA expression level was observed between 5 methanol-slow vs methanol-normal transformants, suggesting that disruption of AOX1 was not essential for efficient HSA expression. As expected, HSA was absent in both the culture medium and the cell extract of GS115/pAO807N transformants (negative control). Clonal variants were selected which demonstrated increased levels of HSA secretion.

10 Example VI

Batch-Fed Fermentation of Mut- *Pichia pastoris* for Production of HSA

15 *Pichia pastoris* GS115:pHSA 413-6 and pPGP1-9-6 were inoculated into two 20 liter Biolafitte fermenters with an 8.5 l working volume. The inoculum was prepared in the following manner: a culture was grown on a YM plate and then transferred to 100 ml YM broth in a shake flask and grown for about 24 hours. 50 mls of this culture was transferred to 1 liter of YM broth in a shake flask and also grown for about 24 hours. 1 liter of this was then transferred to 8.5 liters of fermenter medium in the Biolafitte fermenter. Fermentor medium consisted of Minimal salts + biotin + 5 percent glycerol. Batch growth conditions included the 20 following: pH = 5.8 (controlled with NH<sub>3</sub>), temperature = 30° C, and percent dissolved oxygen greater than 20 percent air saturation.

Glycerol exhaustion was complete after about 24 hours, at which time a slow methanol feed was begun at a rate of 10-15 ml/hr. The methanol concentration was monitored in the fermenter and the feed rate was adjusted to maintain a concentration of 0.5-0.9 percent of methanol in the broth.

25 Secreted HSA in the media was measured quantitatively by densitometry of Coomassie blue stained polyacrylamide gels containing SDS (SDS-PAGE). Areas were referenced to a series of known weights of authentic HSA run on the same SDS-PAGE gels. The data from these gels is included in Tables I and II.

The following Table illustrates the effect of changes in pH on the amount of HSA produced:

30

Table III

35

Production of HSA by Batch- Fed Fermentation				
Run	Strain	pH	HSA g/l	
1	GS115:pPGP1-9-6	5.09-5.32	0.71	
2	GS115:pPGP1-9-6	5.22	0.81	
3	GS115:pPGP1-9-6	5.91	1.28	
4	GS115:pPGP1-9-6	5.78	1.59	
5	GS115:pPGP1-9-6	5.78	1.98	
6	GS115:pPGP1-9-6	5.79	1.32	

The following Table illustrates the level of HSA production which can be achieved at higher pH levels:

45

Table IV

50

Production of HSA by Batch-Fed Fermentation					
Run	Strain	pH	Hours MeOH	Dry Cell Wt.	HSA Broth g/l
1	GS115:pHSA 413-6	5.79	101	ND	2.13
2	GS115:pHSA 413-6	5.85	237	101	3.39
3	GS115:pHSA 413-6	5.85	265	98	2.70
4	GS115:pHSA 413-6	5.97	258	117	2.90

55 ND = Not Determined

Example VII

Protocol for Shake Tube and Shake Flask Secretion of Proteins from *P. pastoris*

For efficient secretion and stable accumulation of HSA in shake tubes and shake flasks it is necessary to use a pH of 5.7-6.4 instead of 5.0 or 5.2 for the fermenter media, to add small amounts yeast extract (0.5-0.1%) and peptone (0.1-0.2%) to the fermenter medium and to start inducing expression at a low cell density (20-25 gram dry cell weight/liter). Using these techniques, we have developed a protocol that permits efficient secretion of HSA from cells grown in shake tubes and flasks. We believe that this protocol is applicable in general to secretion of proteins from *Pichia pastoris*.

10 Shake Tube:

Grow cells to saturation in 10 ml BMGR or BMGY placed in 50 ml tube (2-3 days). The  $A_{600}$  of cells will be in the range of 10-20. Harvest cells, discard the supernatant liquid and resuspend the pellet with 2 ml of BMMR or BMMY. Cover the tube with a sterile gauze or cheese cloth instead of the cap. Return the tube(s) to the shaker and maintain the shaker at about 30°C. At the end of 2-3 days, pellet cells, and analyze supernatant for product. The pellet can be resuspended with fresh media and returned to shaker for renewed secretion. With *Pichia*-HSA strains, 10  $\mu$ l of media supernatant is sufficient for analysis by SDS-PAGE followed by Coomassie staining. Under these conditions, a single band corresponding to HSA size (67 kD) is observed.

20 Shake Flask:

Grow cells as described above in 1 liter of medium (BMGY or BMGR) in a 2 liters flask. Harvest cells and suspend with 50-75 ml of BMMR or BMMY in a fermenter flask (Tunair™ shake-flask fermentation system, Research Products International Corporation) or a baffled flask covered with cheese cloth. Return to the shaker at 30°C and induce for 2-4 days. At the end of 2-4 days the cells are pelleted and the supernatant is analyzed for product. Shake tubes secretion can be re-initiated by resuspending the pelleted cells in fresh media.

30

35

40

45

50

55

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(i) APPLICANT: William D. Prevatt et al.

10 (ii) TITLE OF INVENTION: Expression of Human Serum Albumin in  
*Pichia pastoris*

15 (iii) NUMBER OF SEQUENCES: 3

15 (IV) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: RICHMOND, PHILLIPS, HITCHCOCK & UMPHLETT
- (B) STREET: P.O. Box 2443
- 20 (C) CITY: Bartlesville
- (D) STATE: OK.
- (E) COUNTRY: USA
- 25 (F) ZIP: 74005

30 (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Diskette
- (B) COMPUTER: IBM PC
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: Display Write 4

35 (vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- 40 (C) CLASSIFICATION:

45 (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Hal Brent Woodrow
- (B) REGISTRATION NUMBER: 32,501
- (C) REFERENCE/DOCKET NUMBER: 32819US

50 (ix) TELECOMMUNICATION NUMBER: 1-918-661-0624

## (2) INFORMATION FOR SEQ ID NO:1:

## (1) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 940 bp  
 (B) TYPE: DNA  
 (C) STRANDEDNESS: single  
 10 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Genomic DNA

## 15 (ix) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGATCTAAC	TCCAAAGACG	AAAGGTTGAA	TGAAACCTTT	TTGCCATCCG	ACATCCACAG	60
20 GTCCATTCTC	ACACATAAGT	GCCAAACGCA	ACAGGAGGGG	ATACACTAGC	AGCAGACCGT	120
TGCAAACGCA	GGACCTCCAC	TCCTCTTCTC	CTCAACACCC	ACTTTGCCA	TCGAAAACC	180
AGCCCAGTTA	TTGGGCTTGA	TTGGAGCTCG	CTCATTCCAA	TTCCCTCTAT	TAGGCTACTA	240
25 ACACCATGAC	TTTATTAGCC	TGTCTATCCT	GGCCCCCTG	GCGAGGTTCA	TGTTTGTAA	300
TTTCCGAATG	CAACAAGCTC	CGCATTACAC	CCGAACATCA	CTCCAGATGA	GGGCTTCTG	360
AGTGTGGGT	CAAATAGTT	CATGTTCCC	AAATGGCCA	AAACTGACAG	TTTAAACGCT	420
30 GTCTTGAAC	CTAATATGAC	AAAAGCGTGA	TCTCATCCAA	GATGAACTAA	GTTCGGTTCG	480
TTGAAATGCT	AACGGCCAGT	TGGTCAAAAA	GAAACTTCCA	AAAGTCGGCA	TACCGTTGT	540
35 CTTGTTGGT	ATTGATTGAC	GAATGCTAA	AAATAATCTC	ATTAATGCTT	AGCGCAGTCT	600
CTCTATCGCT	TCTGAACCCC	GGTGCACCTG	TGCCGAAACG	CAAATGGGA	AACACCCGCT	660
TTTGGATGA	TTATGCATTG	TCTCCACATT	GTATGCTCC	AAGATTCTGG	TGGGAATACT	720
40 GCTGATAGCC	TAACGTTCAT	GATCAAATT	TAACTGTTCT	AACCCCTACT	TGACAGCAAT	780
ATATAAACAG	AAGGAAGCTG	CCCTGTCTTA	AACCTTTTT	TTTATCATCA	TTATTAGCTT	840
ACTTCATAA	TTGCGACTGG	TTCCAATTGA	CAAGCTTTG	ATTTAACGA	CTTTAACGA	900
45 CAACTTGAGA	AGATCAAAAA	ACAACTAATT	ATTGAAACG			940

50

55

## (3) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 600 bp  
 (B) TYPE: DNA  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## 10 (ii) MOLECULE TYPE: Genomic DNA

## (ix) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAAGTAAACC	CCATTCAATG	TTCCGAGATT	TAGTATACTT	GCCCCCTATAA	GAAACGAAGG	60
15 ATTCAGCTT	CCTTACCCCCA	TGAACAGAAA	TCTTCCATT	ACCCCCCACT	GGAGAGATCC	120
GCCCAAACGA	ACAGATAATA	GAAAAAAGAA	ATTGGACAA	ATAGAACACT	TTCTCAGCCA	180
ATTAAAGTCA	TTCCATGCAC	TCCCTTTAGC	TGCCGTTCCA	TCCCTTTGTT	GAGCAACACC	240
20 ATCGTTAGCC	AGTACGAAAG	AGGAAACTTA	ACCGATACCT	TGGAGAAATC	TAAGGCGCGA	300
ATGAGTTTAG	CCTAGATATC	CTTAGTGAAG	GGTGTCCGA	TACCTTCTCC	ACATTTCAGTC	360
25 ATAGATGGGC	AGCTTGTAA	TCATGAAGAG	ACGGAAACGG	GCATTAAGGG	TTAACCGCCA	420
AATTATATAA	AAGACAACAT	GTCCCCAGTT	TAAAGTTTTT	CTTCCTTATT	CTTGTATCCT	480
GAGTGACCGT	TGTGTTAAT	ATAACAAGTT	CGTTTAACT	TAAGACCAAA	ACCAGTTACA	540
30 ACAAAATTATA	ACCCCTCTAA	ACACTAAAGT	TCACTCTTAT	CAAACATATCA	AACATCAAAA	600

## 35 (4) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

36 (A) LENGTH: 1830 bp  
 (B) TYPE: DNA  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Genomic DNA

## 45 (ix) SEQUENCE DESCRIPTION: SEQ ID NO:3:

EP 0 510 678 A2

	ATG	AAG	TGG	GTA	ACC	TTT	ATT	TCC	CTT	CTT	TTT	CTC	TTT	AGC	TCG
	Met	Lys	Trp	Val	Thr	Phe	Ile	Ser	Leu	Leu	Phe	Leu	Phe	Ser	Ser
	-35					-30						-25			
5	GCT	TAT	TCC	AGG	GGT	GTG	TTT	CGT	CGA	GAT	GCA	CAC	AAG	AGT	GAG
	Ala	Tyr	Ser	Arg	Gly	Val	Phe	Arg	Arg	Asp	Ala	His	Lys	Ser	Glu
	-20					-15						-10			
10	GTT	GCT	CAT	CGG	TTT	AAA	GAT	TTG	GGA	GAA	GAA	AAT	TTC	AAA	GCC
	Val	Ala	His	Arg	Phe	Lys	Asp	Leu	Gly	Glu	Glu	Asn	Phe	Lys	Ala
	-5					1						5			
15	TTG	GTG	TTG	ATT	GCC	TTT	GCT	CAG	TAT	CTT	CAG	CAG	TGT	CCA	TTT
	Leu	Val	Leu	Ile	Ala	Phe	Ala	Gln	Tyr	Leu	Gln	Gln	Cys	Pro	Phe
	10					15					20				
20	GAA	GAT	CAT	GTA	AAA	TTA	GTG	AAT	GAA	GTA	ACT	GAA	TTT	GCA	AAA
	Glu	Asp	His	Val	Lys	Leu	Val	Asn	Glu	Val	Thr	Glu	Phe	Ala	Lys
	25					30					35				
25	CAT	TGT	GTT	GCT	GAT	GAG	TCA	GCT	GAA	AAT	TGT	GAC	AAA	TCA	CTT
	His	Cys	Val	Ala	Asp	Glu	Ser	Ala	Glu	Asn	Cys	Asp	Lys	Ser	Lue
	55					45					50				
30	ACA	ACC	CTT	TTT	GGA	GAC	AAA	TTA	TGC	ACA	GTT	GCA	ACT	CTT	CGT
	Thr	Cys	Leu	Phe	Gly	Asp	Lys	Leu	Cys	Thr	Val	Ala	Thr	Leu	Arg
	70					60					65				
35	GAA	ACC	TAT	GGT	GAA	ATG	GCT	GAC	TGC	TGT	GCA	AAA	CAA	GAA	CCT
	Glu	Thr	Tyr	Gly	Glu	Met	Ala	Asp	Cys	Cys	Ala	Lys	Gln	Glu	Pro
	85					75					80				
40	GAG	AGA	AAT	GAA	TGC	TTC	TTG	CAA	CAC	AAA	GAT	GAC	AAC	CCA	AAC
	Glu	Arg	Asn	Glu	Cys	Phe	Leu	Gln	His	Lys	Asp	Asp	Asn	Pro	Asn
	100					90					95				
45	CTC	CCC	CGA	TTG	GTG	AGA	CCA	GAG	GTT	GAT	GTG	ATG	TGC	ACT	GCT
	Leu	Pro	Arg	Leu	Val	Arg	Arg	Pro	Val	Asp	Val	Met	Cys	Thr	Ala
	115					105					110				
50	TTT	CAT	GAC	AAT	GAA	GAG	ACA	TTT	TTG	AAA	AAA	TAC	TTA	TAT	GAA
	Phe	His	Asp	Asn	Glu	Glu	Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr	Glu
						120					125				

45

50

## EP 0 510 678 A2

	ATT	GCC	AGA	AGA	CAT	CCT	TAC	TTT	TAT	GCC	CCG	GAA	CTC	CTT	TTC
	Ile	Ala	Arg	Arg	His	Pro	Tyr	Phe	Tyr	Ala	Pro	Glu	Leu	Leu	Phe
5	130					135					140				
	TTT	GCT	AAA	AGG	TAT	AAA	GCT	GCT	TTT	ACA	GAA	TGT	TGC	CAA	GCT
	Phe	Ala	Lys	Arg	Tyr	Lys	Ala	Ala	Phe	Thr	Glu	Cys	Cys	Gln	Ala
10	145					150					155				
	GCT	GAT	AAA	GCT	GCC	TGC	CTG	TTG	CCA	AAG	CTC	GAT	GAA	CTT	CGG
	Ala	Asp	Lys	Ala	Ala	Cys	Leu	Leu	Pro	Lys	Leu	Asp	Glu	Leu	Arg
15	160					165					170				
	GAT	GAA	GGG	AAG	GTT	TCG	TCT	GCC	AAA	CAG	AGA	CTC	AAG	TGT	GCC
	Asp	Glu	Gly	Lys	Val	Ser	Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	Ala
15	175					180					185				
	AGT	CTC	CAA	AAA	TTT	GGA	GAA	AGA	GCT	TTC	AAA	GCA	TGG	GCA	GTA
	Ser	Leu	Gln	Lys	Phe	Gly	Glu	Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val
20	190					195					200				
	GCT	CGC	CTG	AGC	CAG	AGA	TTT	CCC	AAA	GCT	GAG	TTT	GCA	GAA	GTT
	Ala	Arg	Leu	Ser	Gln	Arg	Phe	Pro	Lys	Ala	Glu	215	Phe	Ala	Glu
20	205					210									Val
	TCC	AAG	TTA	GTG	ACA	GAT	CTT	ACC	AAA	GTC	CAC	ACG	GAA	TGC	TGC
25	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys	Val	His	Thr	Glu	Cys	Cys
	220					225					230				
	CAT	GGA	GAT	CTG	CTT	GAA	TGT	GCT	GAT	GAC	AGG	GCG	GAC	CTT	GCC
	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	Arg	Ala	Asp	Leu	Ala
30	235					240					245				
	AAG	TAT	ATC	TGT	GAA	AAT	CAA	GAT	TCG	ATC	TCC	AGT	AAA	CTG	AAG
	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	Ser	Lys	Leu	Lys
35	250					255					260				
	GAA	TGC	TGT	GAA	AAA	CCT	CTG	TTG	GAA	AAA	TCC	CAC	TGC	ATT	GCC
	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His	Cys	Ile	Ala
35	265					270					275				
	GAA	GTG	GAA	AAT	GAT	GAG	ATG	CCT	GCT	GAC	TTG	CCT	TCA	TTA	GCT
40	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser	Leu	Ala
	280					285					290				
	GCT	GAT	TTT	GTT	GAA	AGT	AAG	GAT	GTT	TGC	AAA	AAC	TAT	GCT	GAG
	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala	Glu
45	295					300					305				
	GCA	AAG	GAT	GTC	TTC	TTG	GGC	ATG	TTT	TTG	TAT	GAA	TAT	GCA	AGA
	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg
45	310					315					320				

50

55

EP 0 510 678 A2

	AGG	CAT	CCT	GAT	TAC	TCT	GTC	GTG	CTG	CTG	CTG	AGA	CTT	GCC	AAG
	Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys
325						330									
5	ACA	TAT	GAA	ACC	ACT	CTA	GAG	AAG	TGC	TGT	GCC	GCT	GCA	GAT	CCT
	Thr	Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Ala	Asp	Pro
						345									
340															
10	CAT	GAA	TGC	TAT	GCC	AAA	GTG	TTC	GAT	GAA	TTT	AAA	CCT	CTT	GTG
	His	Glu	Cys	Tyr	Ala	Lys	Val	Phe	Asp	Glu	Phe	Lys	Pro	Leu	Val
						360					365				
355															
15	GAA	GAG	CCT	CAG	AAT	TTA	ATC	AAA	CAA	AAT	TGT	GAG	CTT	TTT	GAG
	Glu	Glu	Pro	Gln	Asn	Leu	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu
						375					380				
370															
15	CAG	CTT	GGA	GAG	TAC	AAA	TTC	CAG	AAT	GCG	CTA	TTA	GTT	CGT	TAC
	Gln	Leu	Gly	Glu	Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Leu	Val	Arg	Tyr
						390					395				
385															
20	ACC	AAG	AAA	GTA	CCC	CAA	GTG	TCA	ACT	CCA	ACT	CTT	GTA	GAG	GTC
	Thr	Lys	Lys	Val	Pro	Gln	Val	Ser	Thr	Pro	Thr	Leu	Val	Glu	Val
						405					410				
400															
25	TCA	AGA	AAC	CTA	GGA	AAA	GTG	GGC	AGC	AAA	TGT	TGT	AAA	CAT	CCT
	Ser	Arg	Asn	Leu	Gly	Lys	Val	Gly	Ser	Lys	Cys	Cys	Lys	His	Pro
						420					425				
415															
30	GAA	GCA	AAA	AGA	ATG	CCC	TGT	GCA	GAA	GAC	TAT	CTA	TCC	GTG	GTC
	Glu	Ala	Lys	Arg	Met	Pro	Cys	Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val
						435					440				
430															
30	CTG	AAC	CAG	TTA	TGT	GTG	TTG	CAT	GAG	AAA	ACG	CCA	GTA	AGT	GAC
	Leu	Asn	Gln	Leu	Cys	Val	Leu	His	Glu	Lys	Thr	Pro	Val	Ser	Asp
						450					455				
445															
35	AGA	GTC	ACC	AAA	TGC	TGC	ACA	GAA	TCC	TTG	GTG	AAC	AGG	CGA	CCA
	Arg	Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser	Leu	Val	Asn	Arg	Arg	Pro
						465					470				
460															
40	TGC	TTT	TCA	GCT	CTG	GAA	GTC	GAT	GAA	ACA	TAC	GTT	CCC	AAA	GAG
	Cys	Phe	Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr	Tyr	Val	Pro	Lys	Glu
						480					485				
475															
45	TTT	AAT	GCT	GAA	ACA	TTC	ACC	TTC	CAT	GCA	GAT	ATA	TGC	ACA	CTT
	Phe	Asn	Ala	Glu	Thr	Phe	Thr	Phe	His	Ala	Asp	Ile	Cys	Thr	Leu
						495					500				
490															
45	TCT	GAG	AAG	GAG	AGA	CAA	ATC	AAG	AAA	CAA	ACT	GCA	CTT	GTT	GAG
	Ser	Glu	Lys	Glu	Arg	Gln	Ile	Lys	Lys	Gln	Thr	Ala	Leu	Val	Glu
						510					515				
505															

50

55

EP 0 510 678 A2

(5) INFORMATION FOR SEQ ID NO:4:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16bp
- (B) TYPE: DNA
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotide

(ix) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGAAACG ATG AAG TGG 16  
Met Lys Trp

(6) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19bp
- (B) TYPE: DNA
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Oligonucleotide

(ix) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTTACCCACT TCATCGTTT 19

(7) INFORMATION FOR SEQ ID NO:6:

#### (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13bp  
(B) TYPE: DNA

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: Oligonucleotide

(ix) SEQUENCE DESCRIPTION: SEQ ID NO:6:

10 TTAGGGCTTAT AAG 13

(8) INFORMATION FOR SEQ ID NO:7:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14bp  
(B) TYPE: DNA  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: Oligonucleotide

(ix) SEQUENCE DESCRIPTION: SEQ ID NO:7:

25 AATTCTTATA AGCC 14

(9) INFORMATION FOR SEQ ID NO:8:

30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 231bp  
(B) TYPE: DNA  
(C) STRANDED: single  
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: Linker Oligonucleotide

(ix) SEQUENCE DESCRIPTION: SEQ ID NO:8:

40 CCTTAGGCTT ATAACATCTC TACATTTAAA AGCATCTCAG CCTACCATGA GAATAAGAGA 60  
AAGAAAATGA AGATCAAAAG CTTATTCATC TGTGTTTCT TTTTCGTTGG TGTAAAGCCA 120  
ACACCCCTGTC TAAAAAAACAT AAATTTCTTT AATCATTTCG CCTCTTTTC TCTGTGCTTC 180  
45 AATTAATAAA AAATGGAAAG AATCTAAAAA AAAAAAAAAAA AAAAGGAATT C 231

50

55

(10) INFORMATION FOR SEQ ID NO:9:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20bp
- (B) TYPE: DNA
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: Oligonucleotide

(ix) SEQUENCE DESCRIPTION: SEQ ID NO:9:

15 CCTTAGGCTT ATAAGAAC 20

Claims

- 20 1. An improved process for the secretion of a heterologous protein in transformed *Pichia pastoris* cells comprising:
  - (a) cultivating in a fermentation broth transformed *Pichia pastoris* cells capable of expressing a heterologous structural gene encoding a secretion signal sequence and a mature heterologous protein, wherein the signal sequence is operably linked to the sequence encoding the mature heterologous protein, under condition suitable for sustaining the viability of said transformed *Pichia pastoris* cells, under suitable conditions for the expression of said heterologous protein by said *Pichia pastoris* cells, and
  - (b) maintaining the pH of said fermentation broth at a pH in the range of 5.7 to 6.4 contemporaneously with the expression of a heterologous protein.
- 25 2. The process of claim 1 wherein the transformed *Pichia pastoris* cells are grown in a batch-fed manner during the expression of HSA and/or the pH of the fermentation broth is maintained during expression of the heterologous protein in the range of pH 5.7 to pH 6.0, preferably at a pH of 5.8.
- 30 3. The process of claim 2 wherein the fermentation broth contains an effective amount of a suitable minimal salts mixture, growth factors and at least one suitable carbon source selected from methanol, glycerol, sorbitol, glucose, fructose and combinations of two or more thereof to maintain the viability of said transformed *Pichia pastoris* cells.
- 35 4. The process of claim 3, wherein after the fermentation broth's carbon source is consumed, the transformed *Pichia pastoris* cells are contacted with methanol wherein the methanol is provided at a rate sufficient to maintain the viability of the *Pichia pastoris* cells in contact therewith and the methanol concentration dose not exceed about 5.0 percent by weight.
- 40 5. An improved process for the expression of HSA in transformed *Pichia pastoris* cells comprising:
  - (a) cultivating in a fermentation broth transformed *Pichia pastoris* cells capable of expressing HSA under conditions suitably for maintaining the viability of said transformed *Pichia pastoris* cells, under suitable conditions for the expression of HSA by said *Pichia pastoris* cells, and
  - (b) contacting said fermentation broth containing the transformed *Pichia pastoris* cells with a suitable amount of added amino acids and peptone to enhance the secretion of HSA contemporaneously with the expression of HSA and,
  - (c) optionally, maintaining the pH of the fermentation broth during expression of the heterologous protein in the range of from 5.7 to 6.0.
- 45 6. The process of claim 1 or 5 wherein *Pichia pastoris* is transformed with a vector selected from a circular plasmid and a linear plasmid, the latter preferably being a linear integrative site-specific vector.

7. The process of claim 6 wherein said linear integrative site-specific vector contains the following serial arrangement:

- a first insertable DNA fragment,
- at least one marker gene, and at least one expression cassette containing a heterologous structural gene encoding a signal sequence and a mature heterologous protein, operably linked to a regulatory region and a 3' termination sequence, and
- a second insertable DNA fragment

wherein the order of the marker gene and cassette of component (b) may be interchanged, and the first and second insertable DNA fragments employed are homologous with separate portions of the *Pichia pastoris* genome wherein the insertable fragments are in the same relative orientation as exist in the *Pichia pastoris* genome.

8. The process of claim 7, wherein the first insertable DNA fragment and the second insertable DNA fragment are obtained from the DNA sequence of a gene from *Pichia pastoris* selected from the AOX1 gene, the p40 gene, the DAS gene, the GAP gene, the PHO1 gene and the HIS4 gene.

9. The process of claim 7 wherein said expression cassette comprises:

- a regulatory region selected from the AOX1 5' regulatory region isolated from *Pichia pastoris*, the p40 5' regulatory region isolated from *Pichia pastoris*, the DAS 5' regulatory region from *Pichia pastoris*, the GAP 5' regulatory region isolated from *Pichia pastoris*, the acid phosphatase promoter isolated from *Saccharomyces cerevisiae*, the galactosidase promoter isolated from *Saccharomyces cerevisiae*, the alcohol dehydrogenase promoter isolated from *Saccharomyces cerevisiae*, the alpha-mating factor promoter isolated from *Saccharomyces cerevisiae* and the glyceraldehyde 3-phosphate dehydrogenase promoter isolated from *Saccharomyces cerevisiae* operably linked to
- a heterologous structural gene encoding a secretion signal sequence and a mature heterologous protein, wherein the mature heterologous protein is selected from the group consisting of tissue plasminogen activator, albumins, lysozyme, interferon and invertase and the secretion signal is selected from the group consisting of a native signal sequence for the heterologous protein, a signal sequence of the *Pichia pastoris* acid phosphatase gene and a signal sequence of the *Saccharomyces cerevisiae* alpha-mating factor gene, and
- a 3' termination sequence from *Pichia pastoris* selected from the 3' termination sequence isolated from the AOX1 gene, the p40 gene, the DAS gene, the GAP gene, the PHO1 gene and the HIS4 gene.

10. The process of claim 7, wherein said marker gene is selected from HIS4 isolated from *Pichia pastoris*, ARG4 isolated from *Pichia pastoris*, SUC2 isolated from *Saccharomyces cerevisiae*, G418<sup>R</sup> gene of Tn903 and G418<sup>R</sup> gene of Tn601.

11. The process of claim 9, wherein the heterologous structural gene encodes the HSA native signal sequence operably linked to the sequence encoding the mature HSA protein.

12. The process of claim 9 wherein the plasmid comprises an autonomously replicating DNA sequence and a marker gene, said marker gene being selected from HIS4 isolated from *Pichia pastoris*, ARG4 isolated from *Pichia pastoris*, SUC2 isolated from *Saccharomyces cerevisiae*, G418<sup>R</sup> gene of Tn903 and G418<sup>R</sup> gene of Tn601.

13. The process of claim 12 wherein said plasmid comprises:

- the AOX1 5' regulatory region isolated from *Pichia pastoris* operably linked to
- a structural gene for HSA encoding a native signal sequence for HSA and a mature HSA protein, wherein the HSA signal sequence is operably linked to the sequence encoding the mature HSA protein operably linked to
- the 3' termination sequence of AOX1 isolated from *Pichia pastoris* operably linked to
- at least one marker gene, preferably a HIS4 gene, and
- a second DNA fragment which is about a 0.19 kilobase sequence of an autonomously replicating DNA sequence.

14. The process of claim 5 wherein the amino acids are provided in the form of yeast extract at a

**EP 0 510 678 A2**

concentration in the range of 1 g/liter to 15 g/liter and/or wherein the peptone is provided at a concentration in the range of 1 g/liter to 50 g/liter.

5

10

15

20

25

30

35

40

45

50

55




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**  
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.